ACIU Financial Statements From 2010 to 2024

ACIU Stock  USD 3.40  0.01  0.29%   
AC Immune financial statements provide useful quarterly and yearly information to potential AC Immune investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on AC Immune financial statements helps investors assess AC Immune's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting AC Immune's valuation are summarized below:
Gross Profit
-56.4 M
Profit Margin
(0.97)
Market Capitalization
337.4 M
Enterprise Value Revenue
3.5554
Revenue
41 M
There are currently one hundred twenty fundamental measures for AC Immune that can be evaluated and compared over time across peers in the sector. All traders should validate AC Immune's latest fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 603.7 M in 2024. Enterprise Value is likely to gain to about 498.1 M in 2024

AC Immune Total Revenue

19.99 Million

Check AC Immune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AC Immune's main balance sheet or income statement drivers, such as Interest Expense of 167.2 K, Selling General Administrative of 8.3 M or Total Revenue of 20 M, as well as many indicators such as Price To Sales Ratio of 38.71, Dividend Yield of 0.0 or PTB Ratio of 2.11. ACIU financial statements analysis is a perfect complement when working with AC Immune Valuation or Volatility modules.
  
Check out the analysis of AC Immune Correlation against competitors.
For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.

AC Immune Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets177.6 M182.8 M132.8 M
Slightly volatile
Other Current Liabilities9.5 M11.1 M7.8 M
Slightly volatile
Total Current Liabilities12.8 M13.6 M10.9 M
Slightly volatile
Total Stockholder Equity158.5 M160.6 M117 M
Slightly volatile
Other LiabilitiesM3.7 M3.8 M
Slightly volatile
Net Tangible Assets145.5 M136.4 M107.8 M
Slightly volatile
Accounts Payable1.4 M1.7 M1.6 M
Very volatile
Cash107.1 M78.5 M80.8 M
Slightly volatile
Other Assets234.4 K415.1 K201.8 K
Slightly volatile
Net Receivables15.8 M15 M4.8 M
Pretty Stable
Other Current Assets6.8 M6.4 M2.4 M
Slightly volatile
Total Liabilities19.1 M22.2 M15.8 M
Slightly volatile
Total Current Assets157.9 M125.2 M118.2 M
Slightly volatile
Common Stock1.5 M2.1 M1.3 M
Slightly volatile
Property Plant Equipment8.5 M8.1 M3.7 M
Slightly volatile
Property Plant And Equipment Net4.7 M6.9 M3.3 M
Slightly volatile
Current Deferred Revenue131.1 K138 K576.9 K
Pretty Stable
Non Current Assets Total60.5 M57.7 M17.3 M
Slightly volatile
Non Currrent Assets Other394.4 K415.1 K624.4 K
Pretty Stable
Cash And Short Term Investments162.9 M103 M110.5 M
Slightly volatile
Common Stock Total Equity1.3 M1.8 M1.2 M
Slightly volatile
Common Stock Shares Outstanding73.3 M84.7 M64.1 M
Slightly volatile
Liabilities And Stockholders Equity193.9 M182.8 M138.5 M
Slightly volatile
Non Current Liabilities Total6.9 M8.6 M5.3 M
Slightly volatile
Capital Surpluse235.2 M398.5 M219.4 M
Slightly volatile
Other Stockholder Equity300.1 M474.8 M224.5 M
Slightly volatile
Property Plant And Equipment Gross18.8 M17.9 M5.5 M
Slightly volatile
Net Invested Capital211.4 M160.6 M158.5 M
Slightly volatile
Net Working Capital137.5 M111.6 M145.3 M
Slightly volatile
Capital Stock1.8 M2.1 M1.5 M
Slightly volatile

AC Immune Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative8.3 M10.6 M6.7 M
Slightly volatile
Total Revenue20 M14.8 M21.4 M
Very volatile
Cost Of Revenue45.8 M54.6 M37 M
Slightly volatile
Total Operating Expenses13.1 M13.8 M38.5 M
Slightly volatile
Depreciation And Amortization1.4 M2.2 MM
Slightly volatile
Other Operating Expenses59.2 M68.4 M45.1 M
Slightly volatile
Research Development46.5 M54.6 M35.6 M
Slightly volatile
Interest Income1.2 MM1.3 M
Very volatile
Reconciled Depreciation1.9 M2.2 M1.2 M
Slightly volatile

AC Immune Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation2.5 M4.4 M1.9 M
Slightly volatile
Begin Period Cash Flow30 M31.6 M73.8 M
Slightly volatile
Depreciation1.3 M2.2 MM
Slightly volatile
Capital Expenditures1.3 M801 KM
Slightly volatile
End Period Cash Flow107.1 M78.5 M80.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio38.7124.055141.8155
Slightly volatile
PTB Ratio2.112.216343.2971
Slightly volatile
Days Sales Outstanding390371188
Pretty Stable
Book Value Per Share1.71.89671.7011
Slightly volatile
Stock Based Compensation To Revenue0.160.29490.2041
Slightly volatile
Capex To Depreciation0.340.36161.1503
Pretty Stable
PB Ratio2.112.216343.2971
Slightly volatile
EV To Sales31.8818.988136.4716
Slightly volatile
Payables Turnover43.932.522945.9271
Pretty Stable
Sales General And Administrative To Revenue0.610.71450.8803
Slightly volatile
Research And Ddevelopement To Revenue2.823.68933.9525
Slightly volatile
Capex To Revenue0.07380.05410.0931
Slightly volatile
Cash Per Share1.641.21671.6653
Slightly volatile
Days Payables Outstanding10.6611.222921.1759
Slightly volatile
Intangibles To Total Assets0.20.27580.2041
Slightly volatile
Current Ratio9.359.21879.5011
Slightly volatile
Tangible Book Value Per Share1.571.30151.5677
Slightly volatile
Receivables Turnover0.930.983718.4056
Very volatile
Graham Number4.015.22754.0951
Slightly volatile
Shareholders Equity Per Share1.71.89671.695
Slightly volatile
Debt To Equity0.00350.00280.0035
Slightly volatile
Capex Per Share0.01470.00950.0157
Slightly volatile
Graham Net Net1.471.08821.4654
Slightly volatile
Revenue Per Share0.170.17480.3509
Very volatile
Interest Debt Per Share0.0020.00210.0057
Pretty Stable
Debt To Assets0.00310.00250.0031
Slightly volatile
Price Book Value Ratio2.112.216343.2971
Slightly volatile
Days Of Payables Outstanding10.6611.222921.1759
Slightly volatile
Ebt Per Ebit0.791.01120.9757
Pretty Stable
Company Equity Multiplier1.451.1381.7164
Slightly volatile
Long Term Debt To Capitalization0.00110.00120.0028
Slightly volatile
Total Debt To Capitalization0.00350.00270.0035
Slightly volatile
Debt Equity Ratio0.00350.00280.0035
Slightly volatile
Quick Ratio9.349.21879.4945
Slightly volatile
Net Income Per E B T1.11.00021.0089
Slightly volatile
Cash Ratio9.05.78186.8812
Slightly volatile
Days Of Sales Outstanding390371188
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.131.01331.0353
Pretty Stable
Price To Book Ratio2.112.216343.2971
Slightly volatile
Fixed Asset Turnover2.042.150115.9595
Slightly volatile
Debt Ratio0.00310.00250.0031
Slightly volatile
Price Sales Ratio38.7124.055141.8155
Slightly volatile
Asset Turnover0.07690.0810.3448
Slightly volatile
Price Fair Value2.112.216343.2971
Slightly volatile

AC Immune Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap603.7 M356 M555.9 M
Slightly volatile
Enterprise Value498.1 M281 M476.2 M
Slightly volatile

ACIU Fundamental Market Drivers

Forward Price Earnings8.3195
Cash And Short Term Investments103 M

ACIU Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
26th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About AC Immune Financial Statements

AC Immune shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although AC Immune investors may analyze each financial statement separately, they are all interrelated. The changes in AC Immune's assets and liabilities, for example, are also reflected in the revenues and expenses on on AC Immune's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue138 K131.1 K
Total Revenue14.8 M20 M
Cost Of Revenue54.6 M45.8 M
Stock Based Compensation To Revenue 0.29  0.16 
Sales General And Administrative To Revenue 0.71  0.61 
Research And Ddevelopement To Revenue 3.69  2.82 
Capex To Revenue 0.05  0.07 
Revenue Per Share 0.17  0.17 
Ebit Per Revenue(3.62)(3.80)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for ACIU Stock Analysis

When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.